BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Laboratoires Thea readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Laboratoires Thea's drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06628947-10889@assetmemo.bio
DTSTAMP:20261121T010136Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:KIO-301: Phase 2 readout est. (NCT06628947)
DESCRIPTION:KIO-301\, phase 2\, Retinitis Pigmentosa.\nStudy: A Phase II St
 udy of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmento
 sa\nEstimated primary completion: August 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/kio-301#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06628947
URL:https://assetmemo.bio/drug/kio-301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
